(Q34349850)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23752772%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

title

New pharmacological approaches for obesity management (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23752772%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

0 references

1 reference

Christian F Rueda-Clausen

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23752772%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Raj Padwal

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23752772%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

3

Arya M Sharma

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23752772%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

publication date

11 June 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23752772%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Endocrinology

2 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23752772%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23752772%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23752772%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

page(s)

467-478

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23752772%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nrendo.2013.113

2 March 2020

exact match

0 references

cites work

The medical care costs of obesity: An instrumental variables approach

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.113

Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.113

Appetite regulation and weight control: the role of gut hormones

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.113

Long-term persistence of hormonal adaptations to weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.113

Effects of experimental weight perturbation on skeletal muscle work efficiency, fuel utilization, and biochemistry in human subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.113

Central nervous system control of food intake

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.113

A history of drugs on the weight list

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.113

Lorcaserin and adiposopathy: 5-HT2c agonism as a treatment for 'sick fat' and metabolic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.113

Valvular heart disease associated with fenfluramine-phentermine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.113

Central nervous system control of food intake and body weight

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.113

Serotonin 2C receptor agonists improve type 2 diabetes via melanocortin-4 receptor signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.113

Multicenter, placebo-controlled trial of lorcaserin for weight management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.113

A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.113

Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.113

Invited review: Aging and energy balance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.113

Comparison of continuous and intermittent anorectic therapy in obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.113

Appetite suppressants. A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.113

Effects on weight reduction and safety of short-term phentermine administration in Korean obese people

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.113

A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.113

Topiramate-induced weight loss: a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.113

Efficacy and safety of topiramate on weight loss: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.113

A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.113

Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.113

Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.113

Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.113

Topiramate in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.113

Rational design of a combination medication for the treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.113

Anatomy and regulation of the central melanocortin system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.113

Hypothalamic opioid-melanocortin appetitive balance and addictive craving

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.113

Naltrexone depot formulations for opioid and alcohol dependence: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.113

Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.113

Combination therapy with naltrexone and bupropion for obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.113

Naltrexone and human eating behavior: a dose-ranging inpatient trial in moderately obese men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.113

Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.113

Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.113

Using the Edmonton obesity staging system to predict mortality in a population-representative cohort of people with overweight and obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.113

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.113

Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.113

Changes in cardiovascular risk associated with phentermine and topiramate extended-release in participants with comorbidities and a body mass index ≥27 kg/m(2)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.113

Bupropion and naltrexone: a review of their use individually and in combination for the treatment of obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.113

An integrated method to determine meaningful changes in health-related quality of life

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.113

Long-term persistence with orlistat and sibutramine in a population-based cohort

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.113

Drug Treatment of Obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.113

Serotonin receptor ligands and the treatment of obesity

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23752772

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

1 reference

https://pubmed.ncbi.nlm.nih.gov/23752772

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Bupropion sustained release and smoking cessation.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23752772

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRENDO.2013.113

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23752772%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1 reference